CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.
CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021
CureVac, Tübingen, Germany
sarah.fakih@curevac.com
Forward-Looking Statements
This press release contains statements that constitute forward looking statements as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the company ) regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company s vaccine and treatment candidates and the company s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as anticipate, intend, believe, estimate, plan, seek, project, or expect, may, will,
DGAP-News: CureVac und Novartis unterzeichnen initiale Vereinbarung zur Produktion des COVID-19-Impfstoffkandidaten CVnCoV finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV
Novartis plans to start manufacturing of the mRNA and bulk drug product of CureVac s COVID-19 vaccine candidate, CVnCoV, in Q2 2021
Anticipated production of up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022 at the Novartis manufacturing site in Kundl, Austria
Further expansion of CureVac s European manufacturing network expected to increase capacity
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / ACCESSWIRE / March 4, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. Following final agree
Investegate |CureVac Announcements | CureVac: CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.